TISSUE INHIBITORS OF METALLOPROTEINASES
金属蛋白酶组织抑制剂
基本信息
- 批准号:2668244
- 负责人:
- 金额:$ 18.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1994
- 资助国家:美国
- 起止时间:1994-03-01 至 2000-02-29
- 项目状态:已结题
- 来源:
- 关键词:HeLa cells active sites antisense nucleic acid chemical structure function collagenase enzyme activity enzyme complex enzyme linked immunosorbent assay enzyme mechanism enzyme model enzyme structure epitope mapping extracellular matrix gene expression human tissue liver cells neutralizing antibody plasminogen polymerase chain reaction protein degradation site directed mutagenesis stromelysin synthetic peptide tissue inhibitor of metalloproteinases
项目摘要
Tissue Inhibitors of Metalloproteinases (TIMP-l and TIMP-2) regulate the
activity of matrix metalloproteinases in the extracellular milieu. Matrix
metalloproteinases collectively degrade most if not all matrix
macromolecules and appear to be responsible for stromal remodeling in many
normal and pathological events. The inhibitors function at two important
levels: by blocking activation of the latent matrix metalloproteinase
precursors and by forming inhibited complexes with the activated forms of
the enzymes. We wish to understand the molecular basis for these functions
and to examine how TIMPs regulate extracellular matrix degradation by live
cells. In Aim 1, we propose to identify those domains and subdomains of
TIMP-1 and TIMP-2 that are important to inhibitory function by peptide-
and antibody- competition approaches and by site-directed mutagenesis of
sequences targeted by initial competition experiments. We also propose to
identify those domains of TIMP-1 and TIMP-2 that are important to forming
complexes with the Mr 72K GL and Mr 92K GL zymogens, and to understand the
basis for these highly specific interactions. In Aim 2, we propose to
examine how TIMPs maintain latency of MMP precursors. We have formulated
the novel hypothesis that TIMPs form zymogen complexes with all MMP
precursors and that they regulate the rate of opening of the Cys-Zn++-
switch which is a prequisite for MMP activation. We will specifically
quantify the extent to which TIMPs modify the rate of switch-opening and
we will seek to demonstrate formation of dissociable complexes between
fibroblast-type collagenase and stromelysin-1 and TIMPs. In Aim 3, the
role of TlMPs in regulating the degradation of collagen fibrils by live
cells will be analyzed. Two cell based systems will be used, one in which
collagen breakdown is naturally blocked because of coexpression of TIMPs
and one in which rapid collagen breakdown is induced by addition of
plasminogen. The function of specific mutant and wildtype TIMPs in
controlling collagen degradation in the plasminogen-supplemented system
will be examined by addition or overexpression of these TIMPs by means of
a vaccinia virus system. In addition, we will seek to establish that
collagen breakdown is blocked in the absence of plasminogen because of
endogenous AMP expression. Our approach will be to downregulate either the
expression (antisense oligonucleotides or RNA) or the activity
(neutralizing peptides antibodies) of one or both TIMPs and to monitor the
effect on collagen degradation. The proposed studies will yield a better
understanding of the natural control and regulation mechanisms that serve
to limit tissue destruction during normal and pathological developments.
金属蛋白酶(TIMP-L和TIMP-2)的组织抑制剂调节
基质金属蛋白酶在细胞外环境中的活性。矩阵
金属蛋白酶共同降解大多数矩阵(如果不是全部)
大分子,似乎负责许多人的基质重塑
正常事件和病理事件。抑制剂在两个重要的功能
级别:通过阻断潜在基质金属蛋白酶的激活
前体并通过形成激活形式的抑制复合物
酶。我们希望了解这些功能的分子基础
并检查TIMP如何通过现场调节细胞外基质降解
细胞。在AIM 1中,我们建议确定
TIMP-1和TIMP-2对于肽 - 抑制功能很重要
和抗体竞争方法以及通过位于位置的诱变
最初竞争实验针对的序列。我们还建议
识别TIMP-1和TIMP-2的域,这些领域对于形成很重要
MR 72K GL和MR 92K GL Zymogens的复合物,并了解
这些高度特定的相互作用的基础。在AIM 2中,我们建议
检查TIMP如何保持MMP前体的延迟。我们已经制定了
Timps与所有MMP形成Zymogen复合物的新假设
前体并调节Cys-Zn ++的打开率 -
开关是MMP激活的先决条件。我们将具体
量化Timps修改开关率的程度和
我们将寻求证明在
成纤维细胞型胶原酶和Stromelysin-1和Timps。在AIM 3中
TLMP在调节现场调节胶原原纤维降解中的作用
细胞将进行分析。将使用两个基于单元的系统,其中一个
由于TIMP的共表达,胶原蛋白分解自然被阻塞
以及通过添加诱导快速胶原蛋白分解的一种
纤溶酶原。特定突变体和野生型TIMP的功能
控制纤溶酶原系统中的胶原蛋白降解
通过添加或过表达这些TIMP的检查
一种离子病毒系统。此外,我们将寻求确定
由于没有纤溶酶原,胶原蛋白分解被阻塞
内源性AMP表达。我们的方法是下调
表达(反义寡核苷酸或RNA)或活性
(中和肽抗体)一个或两个Timps并监测
对胶原蛋白降解的影响。拟议的研究将产生更好的
了解服务的自然控制和调节机制
在正常和病理发展期间限制组织破坏。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY ALLEN ENGLER其他文献
JEFFREY ALLEN ENGLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY ALLEN ENGLER', 18)}}的其他基金
PILOT--ONCOGENES IN ORAL SQUAMOUS CELL CARCINOMA
试点——口腔鳞状细胞癌中的癌基因
- 批准号:
6501051 - 财政年份:2001
- 资助金额:
$ 18.77万 - 项目类别:
相似海外基金
PHARMACOLOGIC BASIS OF SMOOTH MUSCLE HETEROGENEITY
平滑肌异质性的药理学基础
- 批准号:
2392585 - 财政年份:1980
- 资助金额:
$ 18.77万 - 项目类别:
PHARMACOLOGIC BASIS OF SMOOTH MUSCLE HETEROGENEITY
平滑肌异质性的药理学基础
- 批准号:
2685285 - 财政年份:1980
- 资助金额:
$ 18.77万 - 项目类别: